JLABS @ Shanghai

JLABS @ Shanghai


No.1 South building, JinChuang Mansion
No.4560 Jinke Road
Zhangjiang Hi-Tech Park, Pudong District
Shanghai, 201210

The Future of Innovation is here

The World’s Most Populous Country and Second Biggest Economy

A Rising Middle Class: From 2014 to 2030, China is expected to have added 362 million people to the middle class with its size reaching 854 million in or 90% of China’s urban areas.


+362 Million Growth

Fast Facts:

  • World’s largest Population: 1,41 Billion (2017)
  • World’s 2nd largest economy:
  • 14.8% of Global Economy
  • US$ 11.2 trillion (in 2016)
  • Healthcare spending US$357 Billion (2011)

Powering a Nascent Technology Hub


Patent Applications

In 2016, innovators in China filed 43,168 international patents. A 45% growth in applications compared to 2015, putting Chinese applicants on track to overtake the US within three years.



To date the number of returnees in China who choose to work in the biomedical industry has increased steadily by approximately 7%.


Unparalleled R&D spending

China is the world’s second largest R&D spender. The government spent a total of $200 billion on R&D in 2015, with an annual growth rate of 18.3% (2% of its GDP).

A Vibrant Life Science Ecosystem

Patients are Waiting

China is fast becoming a global leader in healthcare innovation. There is a strong underly healthcare service demand driven by a rapidly ageing population, changing lifestyles, an increasing burden of chronic non-communicable diseases, and unprecedented regulatory change.

130 MILLION Hepatitis B patients


435 MILLION ADULTS WITH Diabetes by 2030

Research Productivity Scores

The Scientific American Worldview Scorecard, which analyzes the innovation potential in biotechnology, ranks China 15th in productivity, while the OECD’s 2015 Business Confidence Index notes that Chinese innovator’s position as “struggling ability to compete”, adding that “local executives say that much more is required in terms of building the scientific research base and infrastructure” to succeed in translational research.

Johnson and Johnson in China

A 35-Year Heritage Of Innovation

Johnson & Johnson has invested significantly in China for over 35 years to meet China’s rapidly evolving healthcare needs.

Since the founding of its first joint venture in China in 1985, Xi’an-Janssen Pharmaceutical Ltd., Johnson & Johnson has been an industry leader in the healthcare market. Through the company’s advanced healthcare solutions, Johnson & Johnson helps to bring a positive impact to the health and life quality of Chinese families. Today, Johnson & Johnson’s businesses span across three sectors in China: consumer; pharmaceuticals; medical devices and diagnostics. With 14 wholly owned and joint venture companies operating in China, Johnson &Johnson currently employs approximately 10,000 people across more than 90 locations, including Beijing, Shanghai, Guangzhou, Suzhou and Xi’an.

Johnson & Johnson has invested significantly in innovation in China for over 35 years with a focus on meeting the rapidly evolving healthcare needs of Chinese patients and their families.

Since the founding in 1985 of its first joint venture, Xi’an Janssen Pharmaceutical Ltd., we have been an industry leader in China with healthcare solutions that address some of the country’s biggest healthcare challenges.

Today, Johnson & Johnson’s businesses span 14 wholly owned and joint venture companies operating in China. We employ approximately 10,000 people across more than 90 locations.

We continue to leverage the scale of Johnson & Johnson to build a powerful innovation ecosystem in China through a network of over 650 science professionals in R&D facilities in Beijing, Guangzhou, Shanghai, and Suzhou.

Johnson & Johnson is the first multinational in China to achieve the “end-to-end” R&D model, which nurtures the development of early-discoveries into clinical applications. The achievement exemplifies Johnson & Johnson’s commitment to promoting innovation as a driving force of China’s economic growth.Today, Johnson & Johnson has three R&D organizations with facilities throughout China that cover a broad range of therapeutic areas across our three main business sectors.

Johnson & Johnson’s presence in pharmaceutical R&D includes Janssen China Research & Development, which comprises a Shanghai-based Discovery Center, a Development Center with employees in both Beijing and Shanghai, and Xian Janssen Pharmaceutical Limited. Additionally, specialist therapeutic centers in Beijing and Shanghai include an OTC/Generics Center, a Center for Biologics, a Center for Liver Diseases, Integrated Biometrics Center, and a core R&D lab housed in the Zhangjiang Hi-Tech Park in Shanghai.

Our R&D teams from Depuy-Synthes, Ethicon, Janssen Pharmaceuticals, and Johnson & Johnson Consumer Health Care work together with local partners throughout the country to advance science in both discovery and development. We combine these capabilities with state-of-the-art manufacturing facilities – including new plants in Xi’an and Suzhou for medicines and medical devices, respectively – to ensure we can also deliver these healthcare solutions to the many patients who need them in China and around the world.

In particular, Johnson & Johnson have identified Shanghai as a key regional innovation hub to support our goal, by opening state-of-the-art facilities over the years we have established to create a power hub for innovation.